{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:26:14Z","timestamp":1790429174626,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We compared the proportion of participants achieving first undetectable HIV-1 RNA (VL) in seminal plasma (SP) and blood plasma (BP) in 19 men starting dolutegravir-based regimen at primary HIV infection. At baseline, median VL was 6.5 (interquartile range [IQR], 5.6\u20137.9) and 4.5 (IQR, 3.5\u20135.0) log10 copies\/mL in BP and SP, respectively. Between baseline and week 48, significantly higher proportion of participants achieved first VL below limit of quantification in SP (93.0%) than in BP (84.2%; P = .008). Time to first undetectable VL was 8 weeks in SP (95% confidence interval [CI], 5.6\u201310.4) and 24 weeks in BP (95% CI, 14.1\u201333.9).<\/jats:p>","DOI":"10.1093\/infdis\/jiab336","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T19:12:10Z","timestamp":1624389130000},"page":"116-120","source":"Crossref","is-referenced-by-count":5,"title":["HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection"],"prefix":"10.1093","volume":"225","author":[{"given":"Jade","family":"Ghosn","sequence":"first","affiliation":[{"name":"Service de Maladies Infectieuses, H\u00f4pital Bichat, Infection Modelisation Antimicrobial Evolution, UMR1137, INSERM, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"INSERM, Sorbonne Universit\u00e9, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lascoux-Combe","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses, H\u00f4pital Saint Louis, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie et Toxicologie, H\u00f4pital Bichat, AP-HP, Infection Modelisation Antimicrobial Evolution, INSERM UMR1137, UF301, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Amat","sequence":"additional","affiliation":[{"name":"Institut de M\u00e9decine et d'Epid\u00e9miologie Appliqu\u00e9es-Fondation L\u00e9on Mba, H\u00f4pital Bichat-Claude Bernard, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gabassi","sequence":"additional","affiliation":[{"name":"Service de Virologie, H\u00f4pital Saint Louis, AP-HP, INSERM U944, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh P","family":"Le","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie et Toxicologie, H\u00f4pital Bichat, AP-HP, Infection Modelisation Antimicrobial Evolution, INSERM UMR1137, UF301, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Nzalakanda","sequence":"additional","affiliation":[{"name":"INSERM, Sorbonne Universit\u00e9, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Valin","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Landman","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses, H\u00f4pital Bichat, Infection Modelisation Antimicrobial Evolution, UMR1137, INSERM, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Chaix","sequence":"additional","affiliation":[{"name":"Service de Virologie, H\u00f4pital Saint Louis, AP-HP, INSERM U944, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[{"name":"Service de Virologie, H\u00f4pital Saint Louis, AP-HP, INSERM U944, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"2022010519004675200_CIT0001","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1086\/386333","article-title":"Brief but efficient: acute HIV infection and the sexual transmission of HIV","volume":"189","author":"Pilcher","year":"2004","journal-title":"J Infect Dis"},{"key":"2022010519004675200_CIT0002","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1097\/QAD.0b013e3283303e04","article-title":"Persistent HIV RNA shedding in semen despite effective antiretroviral therapy","volume":"23","author":"Sheth","year":"2009","journal-title":"AIDS"},{"key":"2022010519004675200_CIT0003","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"2022010519004675200_CIT0004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/cid\/cix358","article-title":"Viral kinetics in semen with different antiretroviral families in treatment-naive human immunodeficiency virus-infected patients: a randomized trial","volume":"65","author":"Gutierrez-Valencia","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022010519004675200_CIT0005","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e3282f12377","article-title":"Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase","volume":"21","author":"Murray","year":"2007","journal-title":"AIDS"},{"key":"2022010519004675200_CIT0006","article-title":"Recommandations du groupe d\u2019experts - Sous la direction du Professeur Philippe Morlat et sous l\u2019egide du CNNS et de l\u2019ANRS - Suivi de l\u2019adulte vivant avec le VIH et organisation des soins (avril 2018)","author":"Prise en charge du VIH"},{"key":"2022010519004675200_CIT0007","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1097\/00002030-200409240-00014","article-title":"Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men","volume":"18","author":"Ghosn","year":"2004","journal-title":"AIDS"},{"key":"2022010519004675200_CIT0008","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1093\/jac\/dkw271","article-title":"HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens","volume":"71","author":"Gantner","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022010519004675200_CIT0009","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"2022010519004675200_CIT0010","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022010519004675200_CIT0011","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/COH.0000000000000486","article-title":"Genital reservoir: a barrier to functional cure?","volume":"13","author":"Gantner","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"2022010519004675200_CIT0012","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jac\/dkv425","article-title":"Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake","volume":"71","author":"Elliot","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022010519004675200_CIT0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31829ed7a4","article-title":"Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing","volume":"64","author":"Greener","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022010519004675200_CIT0014","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/infdis\/jiw406","article-title":"HIV-1-RNA decay and dolutegravir concentrations in semen of patients starting a first antiretroviral regimen","volume":"214","author":"Imaz","year":"2016","journal-title":"J Infect Dis"},{"key":"2022010519004675200_CIT0015","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/jac\/dkz482","article-title":"Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir\/abacavir\/lamivudine","volume":"75","author":"Fern\u00e1ndez-Gonz\u00e1lez","year":"2020","journal-title":"J Antimicrob Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab336\/39594667\/jiab336.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/1\/116\/41937300\/jiab336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/1\/116\/41937300\/jiab336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T19:06:14Z","timestamp":1641409574000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/1\/116\/6309026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6,24]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab336","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,6,24]]}}}